Literature DB >> 26475408

Asymmetric dimethylarginine predicts left atrial appendage thrombus in patients with non-valvular atrial fibrillation.

Wei Xia1, Yan Wang1, Tongqing Duan2, Yuanyuan Rong3, Yifan Chi1, Yibing Shao4.   

Abstract

INTRODUCTION: Atrial fibrillation (AF) is associated with increased thrombo-embolic events, with thrombi most frequently located in the left atrial appendage (LAA). Asymmetric dimethylarginine (ADMA), a potent endogenous inhibitor of nitric oxide synthase, is elevated in subjects with AF. We investigated the relationship between ADMA and risk of LAA thrombus in patients with non-valvular AF. METHODS AND
RESULTS: A total of 223 consecutive patients with non-valvular AF were enrolled (63 ± 10 years, 65% male). LAA thrombus was detected in 27 subjects by transesophageal echocardiography. Serum ADMA was significantly increased (2.5 ± 0.6 μmol/L vs 1.8 ± 0.4 μmol/L, p<0.001), while serum nitrite/nitrate was significantly reduced in patients with LAA thrombus (30.3 ± 7.1 μmol/L vs 48.4 ± 9.3 μmol/L, p<0.001). ADMA was positively correlated with age and left atrium diameter, and was negatively correlated with nitrite/nitrate and LAA peak flow velocity. The area under the receiver operating characteristic curve of ADMA predicting thrombus was 0.84. In multivariate logistic regression analysis, ADMA (OR 4.0, 95% CI 1.2-13.0; p=0.003) was one of independent risk factors for LAA thrombus.
CONCLUSIONS: Our study suggested that high ADMA was independently associated with the presence of LAA thrombus in patients with non-valvular AF.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asymmetric dimethylarginine; Atrial fibrillation; Left atrial appendage; Thrombus

Mesh:

Substances:

Year:  2015        PMID: 26475408     DOI: 10.1016/j.thromres.2015.10.021

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  1 in total

1.  Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke.

Authors:  Ilkka Seppälä; Marcus E Kleber; Steve Bevan; Leo-Pekka Lyytikäinen; Niku Oksala; Jussi A Hernesniemi; Kari-Matti Mäkelä; Peter M Rothwell; Cathie Sudlow; Martin Dichgans; Nina Mononen; Efthymia Vlachopoulou; Juha Sinisalo; Graciela E Delgado; Reijo Laaksonen; Tuomas Koskinen; Hubert Scharnagl; Mika Kähönen; Hugh S Markus; Winfried März; Terho Lehtimäki
Journal:  Sci Rep       Date:  2016-03-17       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.